Deglycosylation of HIV-1 AE Gp140 enhances the capacity to elicit neutralizing antibodies against the heterologous HIV-1 clade

AIDS Research and Human Retroviruses

Volumn 26, Issue 5, 2010, Pages 569-575

  Zhang, Congyou ^a,b   Wan, Yanmin ^a   Shi, Jijing ^c   Zhou, Mingzhe ^a   Meng, Zhefeng ^a   Yuan, Songhua ^a   Qiu, Chao ^a   Zhang, Xiaoyan ^a,d   Xu, Xuemei ^b   Liu, Chaoqi ^c   Xu, Jianqing ^a,d  

^a FUDAN UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

^c CHINA THREE GORGES UNIVERSITY   (China)

^d Key Laboratory of Infectious Disease Prevention and Control   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 140; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BAGG ALBINO MOUSE; CELL STRAIN HEK293; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; CROSS REACTION; DEGLYCOSYLATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IN VITRO STUDY; INOCULATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRUS ISOLATION; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; CROSS REACTIONS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GLYCOSYLATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MUTATION; NEUTRALIZATION TESTS; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 77952561004     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0228     Document Type: Article

References (30)

1. Burns DP, Desrosiers RC: Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. Curr Top Microbiol Immunol 1994;188:185-219.
2. Burton DR: Antibodies, viruses and vaccines. Nat Rev Immunol 2002;2:706-713.
3. Kwong PD, Doyle ML, Casper DJ, et al.: HIV-1 evades antibody- mediated neutralization through conformational masking of receptor-binding sites. Nature 2002;420(6916): 678-682.
4. Wei X, Decker JM, Wang S, et al.: Antibody neutralization and escape by HIV-1. Nature 2003;422:307-312.
5. Parren PW, Moore JP, Burton DR, et al.: The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS 1999;13(Suppl A):S137-162.
6. Wyatt R, Sodroski J: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998;280(5371): 1884-1888.
7. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393(6686):648-659.
8. Li Y, Luo L, Rasool N, Kang CY: Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J Virol 1993; 67: 584-588.
9. Li Y, Rey-Cuille MA, Hu SL: N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection. AIDS Res Hum Retrovir 2001; 17:1473-1479.
10. Matthews TJ, Weinhold KJ, Lyerly HK, et al.: Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci USA 1987;84:5424-5428.
11. Ogert RA, Lee MK, Ross W, et al.: N-Linked glycosylation sites adjacent to and within the V1=V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J Virol 2001;75(13):5998-6006.
12. Back NK, Smit L, De Jong JJ, et al.: Glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994;199:431-438.
13. Kolchinsky P, Kiprilov E, Sodroski L: Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 2001;75:2041-2050.
14. McCaffrey RA, Saunders C, Hensel M, et al.: Nlinked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 2004;78:3279-3295.
15. Reitter JN, Means RE, Desrosiers RC: A role for carbohydrates in immune evasion in AIDS. Nat Med 1998;4(6):679-684.
16. Pantophlet R, Saphire EO, Poignard P, et al.: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol 2003; 77: 642-658.
17. Koch M, Pancera M, Kwong PD, et al.: Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003;313(2):387-400.
18. Kolchinsky P, Kiprilov E, Bartley P, et al.: Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1=V2 variable loops. J Virol 2001; 75(7):3435-3443.
19. Ly A, Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol 2000;74(15):6769-6776.
20. Li Y, Cleveland B, Klots I, et al.: Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 2008;82(2):638-651.
21. Bolmstedt A, Sjolander S, Hansen JE, et al.: Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:213-220.
22. Wan Y, Liu L, Wu L, et al.: Deglycosylation or partial removal of HIV-1 CN54 gp140 V1=V2 domain enhances env-specific T cells. AIDS Res Hum Retroviruses 2009;25(6):607-617.
23. Haigwood NL, Nara PL, Brooks E, et al.: Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. J Virol 1992;66:172-182.
24. Xu J, Ren L, Huang X, et al.: Sequential priming and boosting with heterologous HIV immunogens predominantly stimulated T cell immunity against conserved epitopes. AIDS 2006;20(18):2293-2303.
25. Kwong PD, Wyatt R, Robinson J, et al.: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393(6686): 648-659.
26. Hong PW, Nguyen S, Young S, et al.: Identification of the optimal DC-SIGN binding site on human immunodeficiency virus type 1 gp120. J Virol 2007;81(15):8325-18236
27. Lue J, Hsu M, Yang D, et al.: Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1. J Virol 2002;76(20): 10299-10306.
28. Amara RR, Smith JM, Staprans SI, et al.: Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime= recombinant modified vaccinia virus Ankara vaccine. J Virol 2002;76(12):6138-6146.
29. Tagmyer TL, Craigo JK, Cook SJ, et al.: Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J Gen Virol 2007;88(Pt 4):1324-1336.
30. Kim YB, Han DP, Cao C, et al.: Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 2002;305(1): 124-137.